BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Closed|| Long (1Y)
Motilal Oswal Recommends 'Buy' On Laurus Labs
According to Motilal Oswal, in addition to strong base business of API manufacturing under antiretrovirals and Hepatitis C category, Laurus Labs is forward integrating to formulations for regulated markets. The company is also forward integrating in ARVs (antiretrovirals) for further improvement in profitability, the brokerage adds.